Locally delivered plasmin: why should it be superior to plasminogen activators for direct thrombolysis?
With advances in the field of thrombolytic therapy, whereby clots are routinely treated locally via a catheter, traditional systemic thrombolytics such as plasminogen activators might not be the best drugs for this task. Plasmin represents a new class of thrombolytic agents that exhibit direct fibri...
Gespeichert in:
| Veröffentlicht in: | Trends in pharmacological sciences (Regular ed.) 2004-02, Vol.25 (2), p.72-75 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 75 |
|---|---|
| container_issue | 2 |
| container_start_page | 72 |
| container_title | Trends in pharmacological sciences (Regular ed.) |
| container_volume | 25 |
| creator | Novokhatny, Valery V Jesmok, Gary J Landskroner, Kyle A Marder, Victor J Zimmerman, Thomas P |
| description | With advances in the field of thrombolytic therapy, whereby clots are routinely treated locally via a catheter, traditional systemic thrombolytics such as plasminogen activators might not be the best drugs for this task. Plasmin represents a new class of thrombolytic agents that exhibit direct fibrinolytic activity, without the need for either plasminogen or a plasminogen activator. In contrast to plasminogen activators, this independence from plasminogen allows plasmin to efficiently dissolve long, retracted blood clots that are inherently deficient in plasminogen. Preclinical safety studies in rabbits demonstrate that plasmin, in contrast to tissue-type plasminogen activator, does not cause re-bleeding from preformed hemostatic plugs. These results predict that plasmin will prove to be both superior to, and safer than, plasminogen activators in the dissolution of long, retracted blood clots in humans. |
| doi_str_mv | 10.1016/j.tips.2003.12.009 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_71850459</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0165614703003882</els_id><sourcerecordid>71850459</sourcerecordid><originalsourceid>FETCH-LOGICAL-c352t-a65e66344d6aaf19e435f1f1f305c7d6bfe22c1b3fc41a6f825d339e504e5b533</originalsourceid><addsrcrecordid>eNp9kE1rGzEQhkVJSFw3f6CHolNuu9XHatdbCiGYNikYemnPQivN2jJaaytpHfbfV8YOuYU5zGGe94V5EPpMSUkJrb_uy2THWDJCeElZSUj7AS3oquEFb7i4QosMiaKmVXOLPsa4JxnkjN6gWyooYVXLFmi78Vo5N2MDzh4hgMGjU3Gwh2_4ZTfjuPOTM9gm3AGO0wjB-oCTf6X8Fg5Y6WSPKvkQcZ-vxgbQCadd8EPn3RxtfPiErnvlItxd9hL9_fnjz_q52Px--rV-3BSaC5YKVQuoa15Vplaqpy1UXPQ0DydCN6buemBM0473uqKq7ldMGM5bEKQC0QnOl-j-3DsG_2-CmORgowbn1AH8FGVDV5kVbQbZGdTBxxigl2OwgwqzpESe9Mq9POmVJ72SMpn15tCXS_vUDWDeIhefGfh-BiD_eLQQZNQWDhrOTqTx9r3-_yNKjfM</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>71850459</pqid></control><display><type>article</type><title>Locally delivered plasmin: why should it be superior to plasminogen activators for direct thrombolysis?</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><creator>Novokhatny, Valery V ; Jesmok, Gary J ; Landskroner, Kyle A ; Marder, Victor J ; Zimmerman, Thomas P</creator><creatorcontrib>Novokhatny, Valery V ; Jesmok, Gary J ; Landskroner, Kyle A ; Marder, Victor J ; Zimmerman, Thomas P</creatorcontrib><description>With advances in the field of thrombolytic therapy, whereby clots are routinely treated locally via a catheter, traditional systemic thrombolytics such as plasminogen activators might not be the best drugs for this task. Plasmin represents a new class of thrombolytic agents that exhibit direct fibrinolytic activity, without the need for either plasminogen or a plasminogen activator. In contrast to plasminogen activators, this independence from plasminogen allows plasmin to efficiently dissolve long, retracted blood clots that are inherently deficient in plasminogen. Preclinical safety studies in rabbits demonstrate that plasmin, in contrast to tissue-type plasminogen activator, does not cause re-bleeding from preformed hemostatic plugs. These results predict that plasmin will prove to be both superior to, and safer than, plasminogen activators in the dissolution of long, retracted blood clots in humans.</description><identifier>ISSN: 0165-6147</identifier><identifier>EISSN: 1873-3735</identifier><identifier>DOI: 10.1016/j.tips.2003.12.009</identifier><identifier>PMID: 15102492</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Animals ; Fibrinolysin - administration & dosage ; Fibrinolysin - therapeutic use ; Fibrinolytic Agents - administration & dosage ; Fibrinolytic Agents - therapeutic use ; Humans ; Plasminogen Activators - physiology ; Plasminogen Activators - therapeutic use ; Thrombosis - drug therapy</subject><ispartof>Trends in pharmacological sciences (Regular ed.), 2004-02, Vol.25 (2), p.72-75</ispartof><rights>2003 Elsevier Ltd</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c352t-a65e66344d6aaf19e435f1f1f305c7d6bfe22c1b3fc41a6f825d339e504e5b533</citedby><cites>FETCH-LOGICAL-c352t-a65e66344d6aaf19e435f1f1f305c7d6bfe22c1b3fc41a6f825d339e504e5b533</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.tips.2003.12.009$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>315,782,786,3554,27933,27934,46004</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15102492$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Novokhatny, Valery V</creatorcontrib><creatorcontrib>Jesmok, Gary J</creatorcontrib><creatorcontrib>Landskroner, Kyle A</creatorcontrib><creatorcontrib>Marder, Victor J</creatorcontrib><creatorcontrib>Zimmerman, Thomas P</creatorcontrib><title>Locally delivered plasmin: why should it be superior to plasminogen activators for direct thrombolysis?</title><title>Trends in pharmacological sciences (Regular ed.)</title><addtitle>Trends Pharmacol Sci</addtitle><description>With advances in the field of thrombolytic therapy, whereby clots are routinely treated locally via a catheter, traditional systemic thrombolytics such as plasminogen activators might not be the best drugs for this task. Plasmin represents a new class of thrombolytic agents that exhibit direct fibrinolytic activity, without the need for either plasminogen or a plasminogen activator. In contrast to plasminogen activators, this independence from plasminogen allows plasmin to efficiently dissolve long, retracted blood clots that are inherently deficient in plasminogen. Preclinical safety studies in rabbits demonstrate that plasmin, in contrast to tissue-type plasminogen activator, does not cause re-bleeding from preformed hemostatic plugs. These results predict that plasmin will prove to be both superior to, and safer than, plasminogen activators in the dissolution of long, retracted blood clots in humans.</description><subject>Animals</subject><subject>Fibrinolysin - administration & dosage</subject><subject>Fibrinolysin - therapeutic use</subject><subject>Fibrinolytic Agents - administration & dosage</subject><subject>Fibrinolytic Agents - therapeutic use</subject><subject>Humans</subject><subject>Plasminogen Activators - physiology</subject><subject>Plasminogen Activators - therapeutic use</subject><subject>Thrombosis - drug therapy</subject><issn>0165-6147</issn><issn>1873-3735</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kE1rGzEQhkVJSFw3f6CHolNuu9XHatdbCiGYNikYemnPQivN2jJaaytpHfbfV8YOuYU5zGGe94V5EPpMSUkJrb_uy2THWDJCeElZSUj7AS3oquEFb7i4QosMiaKmVXOLPsa4JxnkjN6gWyooYVXLFmi78Vo5N2MDzh4hgMGjU3Gwh2_4ZTfjuPOTM9gm3AGO0wjB-oCTf6X8Fg5Y6WSPKvkQcZ-vxgbQCadd8EPn3RxtfPiErnvlItxd9hL9_fnjz_q52Px--rV-3BSaC5YKVQuoa15Vplaqpy1UXPQ0DydCN6buemBM0473uqKq7ldMGM5bEKQC0QnOl-j-3DsG_2-CmORgowbn1AH8FGVDV5kVbQbZGdTBxxigl2OwgwqzpESe9Mq9POmVJ72SMpn15tCXS_vUDWDeIhefGfh-BiD_eLQQZNQWDhrOTqTx9r3-_yNKjfM</recordid><startdate>20040201</startdate><enddate>20040201</enddate><creator>Novokhatny, Valery V</creator><creator>Jesmok, Gary J</creator><creator>Landskroner, Kyle A</creator><creator>Marder, Victor J</creator><creator>Zimmerman, Thomas P</creator><general>Elsevier Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20040201</creationdate><title>Locally delivered plasmin: why should it be superior to plasminogen activators for direct thrombolysis?</title><author>Novokhatny, Valery V ; Jesmok, Gary J ; Landskroner, Kyle A ; Marder, Victor J ; Zimmerman, Thomas P</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c352t-a65e66344d6aaf19e435f1f1f305c7d6bfe22c1b3fc41a6f825d339e504e5b533</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>Animals</topic><topic>Fibrinolysin - administration & dosage</topic><topic>Fibrinolysin - therapeutic use</topic><topic>Fibrinolytic Agents - administration & dosage</topic><topic>Fibrinolytic Agents - therapeutic use</topic><topic>Humans</topic><topic>Plasminogen Activators - physiology</topic><topic>Plasminogen Activators - therapeutic use</topic><topic>Thrombosis - drug therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Novokhatny, Valery V</creatorcontrib><creatorcontrib>Jesmok, Gary J</creatorcontrib><creatorcontrib>Landskroner, Kyle A</creatorcontrib><creatorcontrib>Marder, Victor J</creatorcontrib><creatorcontrib>Zimmerman, Thomas P</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Trends in pharmacological sciences (Regular ed.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Novokhatny, Valery V</au><au>Jesmok, Gary J</au><au>Landskroner, Kyle A</au><au>Marder, Victor J</au><au>Zimmerman, Thomas P</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Locally delivered plasmin: why should it be superior to plasminogen activators for direct thrombolysis?</atitle><jtitle>Trends in pharmacological sciences (Regular ed.)</jtitle><addtitle>Trends Pharmacol Sci</addtitle><date>2004-02-01</date><risdate>2004</risdate><volume>25</volume><issue>2</issue><spage>72</spage><epage>75</epage><pages>72-75</pages><issn>0165-6147</issn><eissn>1873-3735</eissn><abstract>With advances in the field of thrombolytic therapy, whereby clots are routinely treated locally via a catheter, traditional systemic thrombolytics such as plasminogen activators might not be the best drugs for this task. Plasmin represents a new class of thrombolytic agents that exhibit direct fibrinolytic activity, without the need for either plasminogen or a plasminogen activator. In contrast to plasminogen activators, this independence from plasminogen allows plasmin to efficiently dissolve long, retracted blood clots that are inherently deficient in plasminogen. Preclinical safety studies in rabbits demonstrate that plasmin, in contrast to tissue-type plasminogen activator, does not cause re-bleeding from preformed hemostatic plugs. These results predict that plasmin will prove to be both superior to, and safer than, plasminogen activators in the dissolution of long, retracted blood clots in humans.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>15102492</pmid><doi>10.1016/j.tips.2003.12.009</doi><tpages>4</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0165-6147 |
| ispartof | Trends in pharmacological sciences (Regular ed.), 2004-02, Vol.25 (2), p.72-75 |
| issn | 0165-6147 1873-3735 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_71850459 |
| source | MEDLINE; Access via ScienceDirect (Elsevier) |
| subjects | Animals Fibrinolysin - administration & dosage Fibrinolysin - therapeutic use Fibrinolytic Agents - administration & dosage Fibrinolytic Agents - therapeutic use Humans Plasminogen Activators - physiology Plasminogen Activators - therapeutic use Thrombosis - drug therapy |
| title | Locally delivered plasmin: why should it be superior to plasminogen activators for direct thrombolysis? |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-03T04%3A53%3A15IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Locally%20delivered%20plasmin:%20why%20should%20it%20be%20superior%20to%20plasminogen%20activators%20for%20direct%20thrombolysis?&rft.jtitle=Trends%20in%20pharmacological%20sciences%20(Regular%20ed.)&rft.au=Novokhatny,%20Valery%20V&rft.date=2004-02-01&rft.volume=25&rft.issue=2&rft.spage=72&rft.epage=75&rft.pages=72-75&rft.issn=0165-6147&rft.eissn=1873-3735&rft_id=info:doi/10.1016/j.tips.2003.12.009&rft_dat=%3Cproquest_cross%3E71850459%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=71850459&rft_id=info:pmid/15102492&rft_els_id=S0165614703003882&rfr_iscdi=true |